Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 4,741 shares at $46.18 ($219K) on 2025-05-15, disclosed to the SEC on 2025-05-19.
Open-market sale of $219k PTCT by Executive VP AND CLO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.18 | 1,929 | $89K | 40.7% |
| 2 | $46.18 | 1,929 | $89K | 40.7% |
| 3 | $46.02 | 883 | $41K | 18.6% |
| Total | $46.15 avg | 4,741 | $219K | 100% |
| Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |